Infinimmune Raises $75 Million Series A To Advance Human-Derived Antibody Pipeline
By Amit Chowdhry ● Aug 11, 2026
Infinimmune has raised $75 million in Series A financing to advance a pipeline of fully human antibody therapeutics for atopic dermatitis and other inflammatory diseases. The round was co-led by Regeneron Ventures and Playground Global, with participation from RA Capital Management, Goldcrest Capital, Forge Life Science Partners, Godfrey Capital and Wild Tree Ventures. Existing investors Merck Global Health Innovation Fund, Everbright Biofund, Civilization Ventures and Pear VC also participated.